Fresh Tracks Therapeutics Inc
Change company Symbol lookup
Select an option...
FRTX Fresh Tracks Therapeutics Inc
NKTR Nektar Therapeutics
DHT DHT Holdings Inc
TWCB Bilander Acquisition Corp
WATT Energous Corp
MOVE Movano Inc
CECL Cecil Bancorp Inc
SDPI Superior Drilling Products Inc
IMCC IM Cannabis Corp
STAG STAG Industrial Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Fresh Tracks Therapeutics, Inc., formerly Brickell Biotech, Inc., is a clinical-stage pharmaceutical company engaged in transforming patient lives through the development of differentiated prescription therapeutics. Its pipeline is focused on providing existing treatment paradigms and features several new molecular entities that inhibit novel targets with potential for autoimmune, inflammatory, and other debilitating diseases. The Company’s strategy is exploring therapies by identifying, pursuing, and developing therapeutics that can help people struggling with autoimmune, inflammatory and other debilitating diseases. Its pipeline includes FRTX-02, FRTX-10, Kinase Inhibitors and FRTX-03. Its lead program, FRTX-02, is a clinical-stage oral DYRK1A inhibitor for patients with autoimmune diseases to be administered in humans. Its FRTX-10 is a preclinical-stage stimulator of interferon genes (STING) inhibitor candidate. Its Kinase Inhibitors include compounds that inhibit prominent targets.

Closing Price
$1.60
Day's Change
-0.06 (-3.61%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.71
Day's Low
1.60
Volume
(Average)
Volume:
23,563

10-day average volume:
25,861
23,563

Display:

Providers:

UpdateCancel
6 providers
November 10, 2022
November 03, 2022
September 13, 2022
Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02

EQNX::TICKER_START (NASDAQ:BBI),(NASDAQ:FRTX), EQNX::TICKER_END FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing (Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.